FDA joint repair panel
This article was originally published in The Gray Sheet
Executive Summary
Cellular therapies for the repair and regeneration of joint surfaces will be discussed by CBER's Cellular, Tissue & Gene Therapies Advisory Committee March 3-4. In October, FDA renamed the former Biological Response Modifiers Advisory Committee to reflect its mission more accurately [Editors' note: To view a webcast of the meeting, please visit 1www.fdaadvisorycommittee.com...